Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts

Shares of Tocagen Inc (NASDAQ:TOCA) have been assigned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.

Brokers have set a one year consensus price target of $23.67 for the company and are forecasting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also assigned Tocagen an industry rank of 179 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th.

Hedge funds and other institutional investors have recently modified their holdings of the business. EcoR1 Capital LLC purchased a new stake in shares of Tocagen in the 2nd quarter worth about $18,074,000. FMR LLC purchased a new stake in shares of Tocagen in the 2nd quarter worth about $9,624,000. JPMorgan Chase & Co. boosted its position in shares of Tocagen by 52.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock worth $7,886,000 after buying an additional 218,100 shares in the last quarter. Vanguard Group Inc. purchased a new stake in shares of Tocagen in the 2nd quarter worth about $5,036,000. Finally, Pure Financial Advisors Inc. purchased a new stake in shares of Tocagen in the 4th quarter worth about $1,324,000. Institutional investors own 36.22% of the company’s stock.

Shares of Tocagen (NASDAQ TOCA) traded up $1.29 during midday trading on Friday, hitting $14.12. 234,026 shares of the company’s stock traded hands, compared to its average volume of 142,382. Tocagen has a 52 week low of $8.60 and a 52 week high of $17.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 6.03 and a current ratio of 6.03.

Tocagen (NASDAQ:TOCA) last issued its earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. analysts forecast that Tocagen will post -2.66 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Tocagen Inc (TOCA) Given $23.67 Average Price Target by Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/20/tocagen-inc-toca-given-23-67-average-price-target-by-analysts.html.

Tocagen Company Profile

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply